<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7089181\results\search\testTrace\results.xml">
  <result pre="aspect of countermeasures against viral biothreat agents are the antiviral" exact="treatment" post="options available for use in post-exposure prophylaxis. These issues"/>
  <result pre="in order to be able to provide prophylaxis, isolation, and" exact="treatment" post="for large numbers of exposed and infected individuals. The"/>
  <result pre="others. This requires research into these countermeasures, including the development," exact="testing" post="and stockpiling of vaccines and antiviral drugs, particularly for"/>
  <result pre="and biodefense, mode of action, and give an overview of" exact="treatment" post="options available or in the pipeline. Public health relevance"/>
  <result pre="States Federal Drug Administration [55]. Smallpox as an exclusively human" exact="infection" post="was eradicated by vaccination, but this is impossible for"/>
  <result pre="the case of an acute zoonotic viral infection, post-exposure antiviral" exact="treatment" post="of the unvaccinated is a potentially lifesaving option in"/>
  <result pre="for such infections is woefully small. VHFs are caused by" exact="infection" post="with RNA viruses. The standard of treatment for RNA"/>
  <result pre="are caused by infection with RNA viruses. The standard of" exact="treatment" post="for RNA virus infections where it shows efficacy, is"/>
  <result pre="ribavirin, developed in 1963 [32]. Where possible, early start of" exact="treatment" post="of acute virus infections gives the best results and,"/>
  <result pre="best results and, in this context, accurate and rapid virus" exact="diagnosis" post="is essential. The crucial role of a well-organized public"/>
  <result pre="crucial role of a well-organized public health system and classic" exact="quarantine" post="approaches was demonstrated in the recent Ebola outbreaks in"/>
  <result pre="or improved antiviral drugs are needed for the prevention and/or" exact="treatment" post="of a number of significant conditions caused by viruses"/>
  <result pre="be controlled by alternative measures, including vector control, immunization and" exact="treatment" post="with existing antiviral drugs. The need for specialized BSL-3/BSL-4"/>
  <result pre="the interface between research and industry, and preparedness for the" exact="treatment" post="of infections with biodefense-related viruses followed. Further contributions outlined"/>
  <result pre="vitro toxicity is minimal, the compounds go straight into pharmacokinetics" exact="testing" post="(rodent models), and into animal models of viral infections"/>
  <result pre="[79]. To further select compounds prior to animal testing, complex" exact="infection" post="models, including in vitro 3D models, are currently the"/>
  <result pre="research in the antivirals field [77]. Functional models of virus" exact="infection" post="at barriers, and the effect of antivirals on the"/>
  <result pre="would also result in a significant reduction of unsuccessful drug" exact="testing" post="in animal models. The evaluation cycle described above follows"/>
  <result pre="Platformâ€™ collaboration between Cardiff University and IMB into prophylaxis and" exact="treatment" post="of infections caused by viral biothreat agents, which is"/>
  <result pre="established comprises all steps from molecular design to in vitro" exact="testing" post="in complex infection models. Talks at MBDC 2018 included"/>
  <result pre="steps from molecular design to in vitro testing in complex" exact="infection" post="models. Talks at MBDC 2018 included different examples of"/>
  <result pre="contributions on live cell imaging of virus-infected cells for antivirals" exact="testing" post="in a model of the blood brain barrier (Hurler-MBDC-2018-GP2),"/>
  <result pre="a novel polymerase-inhibiting CHIKV antiviral (MB-70, Hucke-MBDC-2018-GP4), a NS4a autophagy" exact="testing" post="system for flaviviruses (Tscherne-MBDC-2018-GP5), and MoA studies on Cf2642"/>
  <result pre="agents in the order of relevance for biodefense, the FDA-approved" exact="treatment" post="options, and antivirals in development, with top candidates highlighted"/>
  <result pre="to the UK were travel-related. Poxviruses are transmitted by contact" exact="infection" post="and via the respiratory tract, causing a systemic infection"/>
  <result pre="contact infection and via the respiratory tract, causing a systemic" exact="infection" post="in humans and animals. Smallpox virus infection leads to"/>
  <result pre="causing a systemic infection in humans and animals. Smallpox virus" exact="infection" post="leads to a fatal multiorgan failure syndrome within 7â€&quot;14Â"/>
  <result pre="the first effective drugs in clinical use as a parenteral" exact="treatment" post="in severe OPV infections was cidofovir, a bisphosphonate developed"/>
  <result pre="have shown interesting antiviral activity against OPV in in vitro" exact="infection" post="models [27, 153] (TableÂ 1). Filoviridae Filoviruses are category"/>
  <result pre="are potential targets for antiviral drug development. Anti-filovirus drugs. While" exact="treatment" post="recommendations are emphasizing intensive medical support if suitable clinical"/>
  <result pre="emphasizing intensive medical support if suitable clinical facilities and cohort" exact="isolation" post="are available [15, 16], defense against the use of"/>
  <result pre="antiviral drugs against alphaviruses causing arthritis and encephalitis, and the" exact="treatment" post="of infections is mainly supportive (anti-inflammatory drugs, glucocorticoids). Anti-alphavirus"/>
  <result pre="the old antiparasitic suramin, which shows ameliorating effects against CHIKV" exact="infection" post="in mice [82] and the anthelmintic ivermectin, which shows"/>
  <result pre="drugs. Ribavirin is used under compassionate use protocols for the" exact="treatment" post="of LassaF [97, 112], while recently favipiravir was evaluated"/>
  <result pre="ribavirin versus CCHFV [70, 78]. Further interesting candidates for virus-specific" exact="treatment" post="(TableÂ 1) include favipiravir (T-705), which has been evaluated"/>
  <result pre="against a number of phleboviruses (PhleboV) and to treat CCHFV" exact="infection" post="in rodent models [53, 54, 59], galidesivir (BCX4430), effective"/>
  <result pre="59], galidesivir (BCX4430), effective against Rift Valley fever virus (RVFV)" exact="infection" post="in a hamster model and investigated for use by"/>
  <result pre="host cells [42]. Anti-flavivirus drugs. Ribavirin is an effective early" exact="treatment" post="for yellow fever under compassionate use protocols, but fails"/>
  <result pre="[18]. Sofosbuvir was initially developed and approved by FDA for" exact="treatment" post="of hepatitis C. It shows activity against a number"/>
  <result pre="all candidates so far tested in animal models for the" exact="treatment" post="of infections with Usutu (UsutuV), Dengue (DENV) and Zika"/>
  <result pre="respiratory distress with potentially fatal outcomes in humans. In humans," exact="infection" post="of the respiratory tract can lead to pneumonia, secondary"/>
  <result pre="polymerase PA subunit), was approved by the FDA for the" exact="treatment" post="of acute, uncomplicated influenza among patients aged 12Â years"/>
  <result pre="[80, 110]. Favipiravir developed and approved in Japan specifically for" exact="treatment" post="of influenza virus infections, and its combination with neuraminidase"/>
  <result pre="no evidence for efficacy or safety of amantadine for the" exact="treatment" post="of influenza A [6]. However, their structures may still"/>
  <result pre="by many authors, including in the context of yellow fever" exact="treatment" post="[103]. Examples for synergistic effects in combinations of antiviral"/>
  <result pre="of the same or distinct virus families, allowing the empirical" exact="treatment" post="of severe viral infections prior to positive diagnosis of"/>
  <result pre="the empirical treatment of severe viral infections prior to positive" exact="diagnosis" post="of the viral agent. Leading examples are at his"/>
  <result pre="are broad-spectrum viral RNA polymerase inhibitors, initially developed for the" exact="treatment" post="of influenza virus, and found effective against bunyaviruses [21,"/>
  <result pre="mortality in human hosts of all known viral agents and" exact="treatment" post="options are a serious concern both in public health"/>
  <result pre="public health and in biodefense scenarios [67]. If specific antiviral" exact="treatment" post="options are not available, supportive care is the mainstay"/>
  <result pre="Ribavirin (Copegusâ&quot;¢, Rebetolâ&quot;¢, VirazoleÂ® ICN/Valeant (IND)) is used for the" exact="treatment" post="of infections with African arenaviruses (Lujo- and Lassa fever)"/>
  <result pre="However, intravenous ribavirin does not show any benefits for the" exact="treatment" post="of any of the VHFs caused by filoviruses, or"/>
  <result pre="drug development begin with in silico design and go via" exact="testing" post="in single cell types (organotypic cell lines or primary"/>
  <result pre="cell lines or primary cells) to determine IC50/CC50â€‰=â€‰SI, and complex" exact="infection" post="models to animal models, clinical trials, and eventually regulatory"/>
  <result pre="for lack of interest and funding. Human organoids/complex in vitro" exact="infection" post="models (e.g., barrier models) may provide a bridge to"/>
  <result pre="number of compounds currently in the experimental pipeline for clinical" exact="testing" post="is small. Consequently, while there are treatment options, they"/>
  <result pre="pipeline for clinical testing is small. Consequently, while there are" exact="treatment" post="options, they may not be available in sufficient quantity"/>
  <result pre="a biological threat situation. Therefore, research in identification, development, clinical" exact="testing" post="and the stockpiling of approved antivirals in sufficient quantities"/>
  <result pre="of the F1 motif of the viral polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral" exact="treatment" post="efficiently inhibits chikungunya virus infection in the joints of"/>
  <result pre="the viral polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral treatment efficiently inhibits chikungunya virus" exact="infection" post="in the joints of mice during the acute but"/>
  <result pre="virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and monkeypox virus" exact="infection" post="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvÃ£oMGRocha Crispino SantosMAAlves da CunhaAJAmantadine"/>
  <result pre="PI3K/Akt pathway and protects Zika virus-infected A129 mice: a host-targeting" exact="treatment" post="strategyAntivir Res2018160384710.1016/j.antiviral.2018.10.00730326204 25.ChangJWarrenTKZhaoXGillTGuoFWangLComunaleMADuYAlonziDSYuWYeHLiuFGuoJ-TMehtaACuconatiAButtersTDBavariSXuXBlockTMSmall molecule inhibitors of ER Î±-glucosidases are"/>
  <result pre="safety profile of brincidofovir: a favorable benefit-risk proposition in the" exact="treatment" post="of smallpoxAntivir Res201714326927710.1016/j.antiviral.2017.01.00928093339 27.CryerMLaneKGreerMCatesRBurtSAndrusMZouJRogersPHansenMDHBurgadoJPanayampalliSSDayCWSmeeDFJohnsonBFIsolation and identification of compounds from"/>
  <result pre="a dangerous illness. https://www.encephalitis.info/Handlers/Download.ashx?IDMF=9ea058b7-fd6f-493e-8589-34d56e9ac164 29.DawesBEKalveramBIkegamiTJuelichTSmithJKZhangLParkALeeBKomenoTFurutaYFreibergANFavipiravir (T-705) protects against Nipah virus" exact="infection" post="in the hamster modelSci Rep20188760410.1038/s41598-018-25780-329765101 30.De BurghgraeveTSeliskoBKapteinSChatelainGLeyssenPDebingYJacobsMVan AerschotACanardBNeytsJ3â€²,5â€²Di-O-trityluridine inhibits"/>
  <result pre="inhibits In vitro flavivirus replicationAntivir Res20139824224710.1016/j.antiviral.2013.01.01123470860 31.De ClercqECidofovir in the" exact="treatment" post="of poxvirus infectionsAntivir Res20025511310.1016/S0166-3542(02)00008-612076747 32.De ClercqELiGApproved antiviral drugs over"/>
  <result pre="also inhibits chikungunya virus replicationAntimicrob Agents Chemother201910.1128/AAC.01389-1831844010 41.Ferreira-RamosASLiCEydouxCContrerasJMMoriceCQuÃ©ratGGiganteAPÃ©rez PÃ©rezM-JJungM-LCanardBGuillemotJ-CDecrolyECoutardBApproved drugs" exact="screening" post="against the nsP1 capping enzyme of Venezuelan equine encephalitis"/>
  <result pre="derivatives in phlebovirus disease modelsAntivir Res20108612112710.1016/j.antiviral.2009.10.01519874853 55.GrosenbachDWHoneychurchKRoseEAChinsangaramJFrimmAMaitiBLovejoyCMearaILongPHrubyDEOral tecovirimat for the" exact="treatment" post="of smallpoxN Engl J Med2018379445310.1056/NEJMoa170568829972742 56.GrossiIMFosterSAGaineyMRKrileRTDunnJABrundageTKhouriJMEfficacy of delayed brincidofovir"/>
  <result pre="treatment of smallpoxN Engl J Med2018379445310.1056/NEJMoa170568829972742 56.GrossiIMFosterSAGaineyMRKrileRTDunnJABrundageTKhouriJMEfficacy of delayed brincidofovir" exact="treatment" post="against a lethal rabbitpox virus challenge in New Zealand"/>
  <result pre="in a lethal mouse modelJ Infect Dis1999179Suppl 1S240S24710.1086/5143169988190 65.HugginsJWProspects for" exact="treatment" post="of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral"/>
  <result pre="fevers: advancing the level of treatmentBMC Med.2012103110.1186/1741-7015-10-3122458265 68.JabbariATabasiSAbbasiAAlijanpourECrimean-congo hemorrhagic fever:" exact="treatment" post="and control strategy in admitted patientsCasp J Intern Med20123443444"/>
  <result pre="Microbiol200341104894489710.1128/jcm.41.10.4894-4897.200314532254 77.KobanRNeumannMDaugsABlochONitscheALanghammerSEllerbrokHA novel three-dimensional cell culture method enhances antiviral drug" exact="screening" post="in primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of ribavirin"/>
  <result pre="primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of ribavirin in the" exact="treatment" post="of Crimean-Congo hemorrhagic fever in Eastern Black Sea region"/>
  <result pre="available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus" exact="infection" post="in a large animal modelSci Transl Med20146232ra5210.1126/scitranslmed.300851724739760 82.KuoS-CWangY-MHoY-JChangT-YLaiZ-ZTsuiP-YWuT-YLinC-CSuramin treatment"/>
  <result pre="morbillivirus infection in a large animal modelSci Transl Med20146232ra5210.1126/scitranslmed.300851724739760 82.KuoS-CWangY-MHoY-JChangT-YLaiZ-ZTsuiP-YWuT-YLinC-CSuramin" exact="treatment" post="reduces chikungunya pathogenesis in miceAntivir Res2016134899610.1016/j.antiviral.2016.07.02527577529 83.La FraziaSPiacentiniSRiccioARossignolJ-FSantoroMGThe second-generation"/>
  <result pre="virus antiviral targets an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic ribavirin" exact="treatment" post="of dengue type 1 infection in rhesus monkeysAntivir Res19901313914910.1016/0166-3542(90)90029-72353804"/>
  <result pre="virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic ribavirin treatment of dengue type 1" exact="infection" post="in rhesus monkeysAntivir Res19901313914910.1016/0166-3542(90)90029-72353804 93.MaranoGPupellaSPatiIMasielloFFranchiniMVaglioSVelatiCLiumbrunoGMTen years since the last"/>
  <result pre="Chem2013561311132210.1021/jm301778x23320521 100.MercerJHeleniusAVirus entry by macropinocytosisNat Cell Biol20091151052010.1038/ncb0509-51019404330 101.MilliganGNWhiteMZavalaDPylesRBSarathyVVBarrettADTBourneNSpectrum of activity" exact="testing" post="for therapeutics against all four dengue virus serotypes in"/>
  <result pre="Chikungunya virus infectionAntivir Res201815010111110.1016/j.antiviral.2017.12.01229269135 114.Osuna-RamosJFReyes-RuizJMBautista-CarbajalPCervantes-SalazarMFarfan-MoralesCNDe JesÃºs-GonzÃ¡lezLAHurtado-MonzÃ³nAMDel Ã�ngelRMEzetimibe inhibits dengue virus" exact="infection" post="in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick"/>
  <result pre="and climate changeEpidemics201910.1016/j.epidem.2019.05.00331175008 125.RosenkeKFeldmannHWestoverJBHanleyPWMartellaroCFeldmannFSaturdayGLovaglioJScottDPFurutaYKomenoTGowenBBSafronetzDUse of favipiravir to treat lassa virus" exact="infection" post="in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with"/>
  <result pre="combination with ribavirin shows significant effects in reducing chikungunya virus" exact="infection" post="In vitro and In vivoAntivir Res2016127505610.1016/j.antiviral.2016.01.00626794398 127.Schmidt-ChanasitJEssbauerSPetraityteRYoshimatsuKTackmannKConrathsFJSasnauskasKArikawaJThomasAPfefferMScharninghausenJJSplettstoesserWWenkMHeckelGUlrichRGExtensive host sharing"/>
  <result pre="vitro Usutu virus replication and delays disease progression in an" exact="infection" post="model in miceAntivir Res201816013714210.1016/j.antiviral.2018.10.02630385306 129.SheahanTPSimsACGrahamRLet al.Broad-spectrum antiviral GS-5734 inhibits"/>
  <result pre="136.TaylorRKotianPWarrenTPanchalRBavariSJulanderJDoboSRoseAEl-KattanYTaubenheimBBabuYSheridanWPBCX4430â€&quot;a broad-spectrum antiviral adenosine nucleoside analog under development for the" exact="treatment" post="of Ebola virus diseaseJ Infect Public Health20169322022610.1016/j.jiph.2016.04.00227095300 137.TchesnokovEPFengJYPorterDPGÃ¶tteMMechanism of"/>
  <result pre="nitazoxanideAntivir Res201714714214810.1016/j.antiviral.2017.10.00228986103 139.TrostLCRoseMLKhouriJKeilholzLLongJGodinSJFosterSAThe efficacy and pharmacokinetics of brincidofovir for the" exact="treatment" post="of lethal rabbitpox virus infection: a model of smallpox"/>
  <result pre="virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 145.WestoverJBMathisATaylorRWanderseeLBaileyKWSefingEJHickersonBTJungK-HSheridanWPGowenBBGalidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment"/>
  <result pre="virus infection and disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel" exact="treatment" post="of a vaccinia virus infection from an occupational needlestickâ€&quot;San"/>
  <result pre="Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment of a vaccinia virus" exact="infection" post="from an occupational needlestickâ€&quot;San Diego, CaliforniaMMWR Morb Mortal Wkly"/>
 </snippets>
</snippetsTree>
